Premium
Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions
Author(s) -
Glitza Isabella C.,
Smalley Keiran S. M.,
Brastianos Priscilla K.,
Davies Michael A.,
McCutcheon Ian,
Liu James K. C.,
Ahmed Kamran A.,
Arrington John A.,
Evernden Brittany R.,
Smalley Inna,
Eroglu Zeynep,
Khushalani Nikhil,
Margolin Kim,
Kluger Harriet,
Atkins Michael B.,
Tawbi Hussein,
Boire Adrienne,
Forsyth Peter
Publication year - 2020
Publication title -
pigment cell and melanoma research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.618
H-Index - 105
eISSN - 1755-148X
pISSN - 1755-1471
DOI - 10.1111/pcmr.12861
Subject(s) - summit , melanoma , medicine , disease , translational research , cancer , basic research , intensive care medicine , cancer research , pathology , library science , computer science , physical geography , geography
In February 2018, the Melanoma Research Foundation and the Moffitt Cancer Center hosted the Second Summit on Melanoma Central Nervous System Metastases in Tampa, Florida. The meeting included investigators from multiple academic centers and disciplines. A consensus summary of the progress and challenges in melanoma parenchymal brain metastases was published (Eroglu et al., Pigment Cell & Melanoma Research , 2019, 32, 458). Here, we will describe the current state of basic, translational, clinical research, and therapeutic management, for melanoma patients with leptomeningeal disease. We also outline key challenges and barriers to be overcome to make progress in this deadly disease.